Please login to the form below
Alzheimer's
This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.
Research finds a third with dementia concerns face long wait for medical help
A new survey to mark Dementia Action Week (15-21 May) by Alzheimer’s Society reveals staggering statistics surrounding the confusion of symptoms of dementia and old age. ... Kate Lee, chief executive officer of Alzheimer’s Society, said the charity
Latest news
-
Eli Lilly’s Alzheimer’s drug shown to significantly slow disease progression in phase 3 trial
Donanemab slowed the progression of early Alzheimer’s disease by 35% compared to placebo. ... Eli Lilly’s experimental Alzheimer’s drug, donanemab, has been shown to significantly slow cognitive and functional decline in patients with early-stage
-
Biogen and Eisai’s Alzheimer’s drug associated with positive long-term health outcomes
Biogen and Eisai’s Alzheimer’s disease (AD) drug has been predicted to have a positive effect on long-term health outcomes, according to a new article published by Eisai in ... This decision was based on phase 2 data showing that Leqembi reduced the
-
Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
Its experimental Alzheimer’s drug, donanemab, was rejected for accelerated approval by the US Food and Drug Administration in January this year due to the company not submitting enough trial data ... Lilly entered into a partnership with Roche last
-
Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
to accelerate the ecosystem to aid in a timely and accurate diagnosis of Alzheimer’s.". ... The partnership comes just two months after Eisai and Biogen’s Alzheimer’s drug Leqembi (lecanemab-irmb) received accelerated approval in the US for
-
Alzheimer’s Association report highlights need to improve patient-physician communication
A new report from the Alzheimer’s Association has highlighted a need to improve patient-physician communication surrounding cognitive concerns. ... monitor disease progression and treat when appropriate,” said Maria Carrillo, chief science officer,
More from news
Approximately 194 fully matching, plus 429 partially matching documents found.
Latest Intelligence
-
Congress is in session – how companies are boosting their impact and engagement
A look through the calendar for the next few months shows delegates coming together for conditions ranging from Alzheimer’s through to cardiology and urology, and journeying from Amsterdam to Vancouver ... From a pharma company’s perspective, a well-
-
A relentless commitment to neuroscience
It stops time and halts joy because of troublesome dyskinesia. This is Parkinson’s disease. ... Alzheimer’s disease, schizophrenia and other neurological and psychiatric disorders.
-
Preparing for a new era in Alzheimer’s disease
By Charlotte Maule. With the potential approval of the first disease-modifying treatment (DMT) for Alzheimer’s disease (AD) on the horizon – and further treatment candidates in development – stakeholders need to ... Organization. Diagnosis of
-
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
Dr Susan Mitchell, head of policy at Alzheimer’s Research UK, said: “Addressing health inequalities is a key part of the challenge of tackling dementia. ... the impact of higher levels of the p-tau181, a protein strongly associated with markers of
-
Alzheimer’s disease: the search for a cure
Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein. ... other than the build-up of the hallmark Alzheimer’s proteins, amyloid and tau.
More from intelligence
Approximately 9 fully matching, plus 46 partially matching documents found.
Latest appointments
-
Hanover Health appoints James Mole as a director
Speaking on his appointment, Mole said: “It’s great to join Hanover Communications. ... With fifteen years’ experience of working with government, parliament and healthcare charities – including Cancer Research UK, Diabetes UK and the Alzheimer's
-
Cognite strengthens team with two new additions
She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science
-
Metrion Biosciences establishes scientific advisory board
The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.
-
J&J’s clinical research neuroscience director joins MedAvante
Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition
-
Asceneuron appoints chief medical officer
He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.
More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest from PMHub
-
Spotting the Signs of Dementia is the First Step to Diagnosis
Common signs of Alzheimer's disease include difficulties with:. Remembering recent conversations or events. ... It is the second most common type of dementia after Alzheimer's disease.
-
In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
The RISE study includes a research registry created to help ensure the LGBTQIA+ community is represented in Alzheimer’s research.
-
Rare Disease Day – looking to the future with hope
Alzheimer’s disease). ... One of IRDiRC’s goals is to stimulate the development and approval of 1, 000 new therapies for rare diseases by 2027.
-
Article
A glimmer of hope for Alzheimer’s patients, but at what cost? ... Alzheimer’s disease.
-
The future of dementia and the important role of healthcare communication in raising awareness
Caring for people with dementia on hospital wards. London: Alzheimer's Society; 2009. ... Dementia UK: report to the Alzheimer’s society. London: Alzheimer’s Society; 2014.
More from PMHub
Approximately 3 fully matching, plus 27 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Amgen reports positive results for Otezla in psoriatic arthritis
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Adaptive innovation
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- Navigating patients step by step on their clinical trial journey
- Innovative Trials responds to national recommendations to tackle UK clinical trial decline
No results were found
PMHub
IPG Health Medical Communications
We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...
Latest intelligence
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
